drugset / Trial / NCT01375075

A Study of LY2484595 in Japanese Subjects

NCT01375075

Phase 2 Completed 165 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese participants.

Timeline

Start
2011-06
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg Oral
Subject Evacetrapib Small molecule 30 mg Oral
Subject Evacetrapib Small molecule 100 mg Oral
Subject Evacetrapib Small molecule 500 mg Oral

Indications